Citi provided color on Amylin Pharmaceuticals AMLN. In a research report published today, Citi commented on the company's new drug Bydureon.
In the report, Citi states, “Amylin presented a poster at the ADA meeting showing the QTcF (heart
conduction) data on Bydureon… The data showed that Bydureon did not lead to any concerning
increase in the QTc interval in diabetics and there was no correlation between change
in corrected QT interval and exenatide concentrations or renal status. This suggests
that the upcoming tQT study will be clean and we expect that Bydureon will be
approved in early Q2:12 after filing in late Q3/early Q4:11.”
At the moment, Citi has a Hold rating and a price target of $15 placed on the company's stock. On Monday, Amylin closed the day at $12.68. Its shares added 1.66% to their value in today's pre-market trading to trade around $12.89.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in